Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Stopped early · Phase 2

Conditions studied: Relapsed/Refractory Large B Cell Lymphoma

In brief

The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma

Key facts

Study ID

NCT05714345

Run by

Allogene Therapeutics

People needed

2

Starts

2023-11-01

Expected to finish

2024-10-28

Last updated by the study team

2026-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse
• Relapsed or refractory disease after at least 2 lines of chemotherapy
• ECOG performance status 0 or 1
• Absence of significant donor (product)-specific anti-HLA antibodies (DSA)
• Adequate hematological, renal and liver function

You may not qualify if…

• Active central nervous system involvement by malignancy
• Autologous or allogeneic HSCT within last 6 months prior to lymphodepletion
• Hypocellular bone marrow for age

Where it is running

• University of Louisville James Graham Brown Cancer Center — Louisville, Kentucky, United States
• Universitair Ziekenhuis Brussel — Brussels, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.